Now showing items 1-6 of 6

    • ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. 

      Dillon, MT; Bergerhoff, KF; Pedersen, M; Whittock, H; Crespo-Rodriguez, E; Patin, EC; Pearson, A; Smith, HG; Paget, JTE; Patel, RR; Foo, S; Bozhanova, G; Ragulan, C; Fontana, E; Desai, K; Wilkins, AC; Sadanandam, A; Melcher, A; McLaughlin, M; Harrington, KJ (2019-06)
      PURPOSE:ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published about the effect of these drugs on the tumor ...
    • CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. 

      Barker, HE; Patel, R; McLaughlin, M; Schick, U; Zaidi, S; Nutting, CM; Newbold, KL; Bhide, S; Harrington, KJ (2016-09)
      Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer-related deaths, with increasingly more cases arising due to high-risk human papillomavirus (HPV) infection. Cisplatin-based chemoradiotherapy is a ...
    • Dicentric Dose Estimates for Patients Undergoing Radiotherapy in the RTGene Study to Assess Blood Dosimetric Models and the New Bayesian Method for Gradient Exposure. 

      Moquet, J; Higueras, M; Donovan, E; Boyle, S; Barnard, S; Bricknell, C; Sun, M; Gothard, L; O'Brien, G; Cruz-Garcia, L; Badie, C; Ainsbury, E; Somaiah, N (2018-12)
      The RTGene study was focused on the development and validation of new transcriptional biomarkers for prediction of individual radiotherapy patient responses to ionizing radiation. In parallel, for validation purposes, this ...
    • Mutational signatures of ionizing radiation in second malignancies. 

      Behjati, S; Gundem, G; Wedge, DC; Roberts, ND; Tarpey, PS; Cooke, SL; Van Loo, P; Alexandrov, LB; Ramakrishna, M; Davies, H; Nik-Zainal, S; Hardy, C; Latimer, C; Raine, KM; Stebbings, L; Menzies, A; Jones, D; Shepherd, R; Butler, AP; Teague, JW; Jorgensen, M; Khatri, B; Pillay, N; Shlien, A; Futreal, PA; Badie, C; ICGC Prostate Group; McDermott, U; Bova, GS; Richardson, AL; Flanagan, AM; Stratton, MR; Campbell, PJ (2016-09-12)
      Ionizing radiation is a potent carcinogen, inducing cancer through DNA damage. The signatures of mutations arising in human tissues following in vivo exposure to ionizing radiation have not been documented. Here, we searched ...
    • p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. 

      Yogev, O; Barker, K; Sikka, A; Almeida, GS; Hallsworth, A; Smith, LM; Jamin, Y; Ruddle, R; Koers, A; Webber, HT; Raynaud, FI; Popov, S; Jones, C; Petrie, K; Robinson, SP; Keun, HC; Chesler, L (2016-05)
      Neuroblastoma is the most common childhood extracranial solid tumor. In high-risk cases, many of which are characterized by amplification of MYCN, outcome remains poor. Mutations in the p53 (TP53) tumor suppressor are rare ...
    • Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. 

      Dillon, MT; Barker, HE; Pedersen, M; Hafsi, H; Bhide, SA; Newbold, KL; Nutting, CM; McLaughlin, M; Harrington, KJ (2017-01)
      AZD6738 is an orally active ATR inhibitor (ATRi) currently in phase I clinical trials. We found in vitro growth inhibitory activity of this ATRi in a panel of human cancer cell lines. We demonstrated radiosensitization by ...